Skip to content
CancerIndex

Publication

NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker.

Authors not recorded

Mod Pathol2020PMID 32327700stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
32327700
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
NFATC2 Fusion1
(diagnostic)Round Cell Sarcoma with EWSR1-non-ETS FusionDiagnosticCSupports Positive2accepted
EID12692

This case series presented 7 NFATC2-rearranged sarcomas, including 4 EWSR1::NFATC2 and 3 FUS::NFATC2 cases, and developed an ACAN-encoding aggrecan immunohistochemistry as a diagnostic tool for these … (full text at CIViC)

PMID 32327700 · Perret et al., 2020 · Open in CIViC

civic